Inside the research

IQVIA Holdings Inc.

IQV Research profile · latest available data

Price overview

$270.37

▼ -4.65 (-1.7%)

52w hi$275.02
52w lo$156.66
Vol1.10M
As of25 Sep 2026

The Verdict

Hold

Our score +0.43

Short+0.44
Medium+0.54
Long+0.20

computed 2026-09-27

Key fundamentals

IQVIA Holdings Inc.

Healthcare · Diagnostics & Research

Market cap$44.50B
Enterprise value$58.81B
Trailing P/E33.67x
Forward P/E18.70x
EV / EBITDA19.29x
P / S (ttm)2.62x
Profit margin8.1%
Return on equity22.8%
Revenue growth+8.7%
Earnings growth-0.6%
Debt / equity257.98

Layer Breakdown

LayerRawContribution
Fundamental+0.16
Sector+0.08
Technical+0.34
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

United States · www.iqvia.com

Risk Metrics

Beta vs SPX1.00
Corr SPX0.40
Annual vol39.8%
Annual ret+13.4%
Sharpe0.34
Max DD-43.1%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$228.60
High / Low$287.00 / $195.00
Median$223.00
Analysts20
Strong Buy4
Buy17
Hold2
Sell0
Strong Sell0

Recent rating actions

2026-04-08Evercore ISI Group→ Outperform
2026-03-09TD Cowen→ Buy
2026-03-06Barclays→ Overweight
2026-03-03RBC Capital→ Outperform
2026-02-19Truist Securities→ Buy
2026-02-06UBS→ Buy

Officers & Board

FounderDennis Gillings current

Material Events

DateEvent8-K
2026-07-28Earnings Release, Exhibitsread
2026-06-11Material Agreement, Material Obligation…read
2026-06-04Other Material Event, Exhibitsread
2026-06-03Other Material Event, Exhibitsread
2026-05-07Other Material Event, Exhibitsread
2026-05-05Earnings Release, Exhibitsread
2026-04-23Officer / Director Change, Shareholder Vote…read
2026-02-05Earnings Release, Exhibitsread
2025-12-09Material Agreement, Material Obligation…read
2025-11-05Officer / Director Change, Reg FD Disclosure…read
2025-10-28Earnings Release, Exhibitsread
2025-09-02Officer / Director Change, Reg FD Disclosure…read

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share96.3%
HHI4,413 (concentrated)

Top Holders

HolderValueShares
State Street Corp$1.45B7.51M
AQR Capital Management$296.95M1.54M
Fidelity / FMR LLC$234.31M1.21M
Millennium Management$105.31M545.02K
Capital Research / Capital World$99.29M513.86K
Citadel Advisors$78.71M407.37K
Bridgewater Associates$5.06M26.21K
T. Rowe Price Group$67.88K351.28K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-044view
2026-08-044view
2026-07-314view
2026-07-314view
2026-07-314view
2026-07-288-Kview
2026-07-2810-Qview
2026-07-164view
2026-07-164view
2026-07-164view
2026-07-164view
2026-06-118-Kview
2026-06-048-Kview
2026-06-038-Kview
2026-05-114view

The Long Run

FY 2013–2025 · 13 years

LineLatestCAGRTrend
Revenue$16.31B+10.2%
Operating income$2.18B+30.2%
Net income$1.36B+16.1%
Cash from ops$2.15B+14.0%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$274.90$274.90$269.43$270.371.10M
Sep 24$266.46$277.13$266.46$275.021.89M
Sep 23$270.66$277.40$267.42$267.861.12M
Sep 22$270.25$272.44$267.26$270.09950.70K
Sep 21$266.76$270.86$265.25$269.881.93M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →